SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
M3 Module 5: PH10
Acute myeloid leukemia, M2
AML with maturation
FAB M2, NOS
Characterized by the presence of >20% blasts in the bone marrow or peripheral blood. There is evidence of maturation (>=10% maturing cells of neutrophil lineage); cells of monocyte lineage compromise <20% of BM cells.
Patients often present with symptoms related to anemia, thrombocytopenia and neutropenia. The provisional diagnosis during workup may include RA with excess blasts, AML without maturation, AML with maturation, and acute myelomonocytic leukemia. The immunophenotyping information listed below is useful only because it shows those factors that are positive for all myeloid leukemias. The bone marrow only identifies a myeloid neoplasm. Neither the bone marrow biopsy nor the immunophenotyping provide a definitive diagnosis of AML with maturation.